




PHARMACEUTICAL 2023

Alaunos Therapeutics Inc.
Rank 242 of 446





RealRate

PHARMACEUTICAL 2023

Alaunos Therapeutics Inc. Rank 242 of 446



The relative strengths and weaknesses of Alaunos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Alaunos Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 63%, being 19% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	53,799
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,166
Liabilities, Non-Current	28
Other Assets	2,678
Other Compr. Net Income	0
Other Expenses	-133
Other Liabilities	2,188
Other Net Income	-2,625
Other Revenues	2,922
Property and Equipment	8,460
Research and Development	25,018
Selling, General and Administrative Expense	13,142

Output Variable	Value in 1000 USD
Assets	64,937
Liabilities	26,382
Expenses	38,027
Revenues	2,922
Stockholders Equity	38,555
Net Income	-37,730
Comprehensive Net Income	-37,730
Economic Capital Ratio	63%